1443470-24-3

Basic information

• Product Name: C₃₀H₃₉N₅O₉S
• CAS NO: 1443470-24-3
• Molecular Weight: 645.734
• Mol File: 1443470-24-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: C₃₀H₃₉N₅O₉S(CAS DataBase Reference)
• NIST Chemistry Reference: C₃₀H₃₉N₅O₉S(1443470-24-3)
• EPA Substance Registry System: C₃₀H₃₉N₅O₉S(1443470-24-3)

Safety Data

• Hazardous Substances Data: 1443470-24-3(Hazardous Substances Data)

Upstream product

• 581106-09-4 ethyl 2-[({[(2-hydroxyethyl)amino]carbonyl}oxy)methyl]-5,7-dimethyl-3-{2-[(methylamino)sulfonyl]phenyl}-4-oxo-3,4-dihydroquinazoline-6-carboxylate 
• 1606-01-5 2-(diethylamino)acetic acid 

Relevant articles and documents

An effective prodrug strategy to selectively enhance ocular exposure of a cannabinoid receptor (CB1/2) agonist

Glaucoma is a leading cause of vision loss and blindness, with increased intraocular pressure (IOP) a prominent risk factor. IOP can be efficaciously reduced by administration of topical agents. However, the repertoire of approved IOP-lowering drug classes is limited, and effective new alternatives are needed. Agonism of the cannabinoid receptors CB1/2 significantly reduces IOP clinically and experimentally. However, development of CB 1/2 agonists has been complicated by the need to avoid cardiovascular and psychotropic side effects. 1 is a potent CB1/2 agonist that is highly excluded from the brain. In a phase I study, compound 1 eyedrops were well tolerated and generated an IOP-lowering trend but were limited in dose and exposure due to poor solubility and ocular absorption. Here we present an innovative strategy to rapidly identify compound 1 prodrugs that are efficiently metabolized to the parent compound for improved solubility and ocular permeability while maintaining low systemic exposures.